Cumberland Pharmaceuticals Inc. may not be a traditional biotech, but it's still the first drug company to price an initial public offering since Bioheart Inc.'s measly $5.8 million debut 15 months ago. (BioWorld Today)

While biotech financing lagged in the first quarter, activity picked up in the second quarter, and it looks as if the third quarter is off to a fairly decent start. (BioWorld Today)